candidate Covaxin will be conducted in three phases, AIIMS director Randeep Guleria told reporters on Monday.
Guleria, addressing the media, also said that the transmission of the virus in the national capital, barring certain areas, seems to have hit its peak.
Here is look at the what AIIMS director said on India’s Covid vaccine, mortality ratio and cases in Delhi
Vaccine trial in three phases
The trial of India’s vaccine candidate Covaxin will be conducted in three phases by AIIMS.
Phase 1 vaccine trial will be conducted on healthy people aged 18-55 years who have no co-morbidity. The samples of 375 people will be studied in this phase.
The minimum time required for Phase 1 trial results to come out will be four to six weeks. Pregnant women will not be allowed to be a part of the trial in the first phase.
“In the first phase, we see the safety of the vaccine which is of primary importance and the dose range is also calculated,” the Guleria said.
Phase 2 vaccine trial will be conducted on healthy people aged 12-65 years. This phase will study samples from 750 people.
In the second phase, “we see how immunogenic it is and that is subsequently followed by phase III, which involves a larger population to assess its efficacy and therapeutic benefit”, Guleria said.
AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research (ICMR) for conducting Phase I and II randomised, double-blind and placebo-controlled clinical trials of Covaxin.
Phase 3 trial will be conducted to test the efficacy and effectiveness of the vaccine.
Already, around 1,800 people have registered for the trial at AIIMS. Anybody willing to participate in the trial can send an email to [email protected], or an SMS to or call to 7428847499, Rai said.
Last week on Saturday, the country’s leading medical institute had announced that it has given its approval for conducting human clinical trials of Covaxin vaccine candidate starting from Monday. The vaccine candidate has been developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology.
Vaccine should be ready by end of 2020 or early next year, if everthing goes as per plan: AIIMS Director
Asked when a vaccine would be available, Guleria said — “So, predicting exactly when the vaccine is going to be ready is a difficult business. But then say if everything works out ideally, then by the end of the year or early next year, we should be in a position to say that we can start manufacturing. But then there are lot of ifs and buts in that.
“We are very good in mass production. Even if a vaccine comes from any part of the world, India will be involved in its production